A Multicenter, Randomized, Double-Blind, Exploratory Clinical Trial to Evaluate the Efficacy and Safety in Concomitant Administration of Macitentan and Dapagliflozin in Patients With Heart Failure With Mildly Reduced and Preserved Ejection Fraction (HFmrEF and HFpEF) and Combined Pre- and Post-capillary Pulmonary Hypertension (CpcPH)
Official Summary
This clinical trial will evaluate whether combination therapy with Dapagliflozin + Macitentan improves outcomes compared to Dapagliflozin + placebo in patients with combined pre- and post-capillary pulmonary hypertension (CpcPH). The study will measure changes in pulmonary vascular resistance, NT-proBNP, 6-minute walk distance, and quality of life (KCCQ scores) over 24 weeks. Participants will be randomly assigned to one of two groups, take study medication for 24 weeks, and undergo regular clinical, laboratory, and safety assessments.
Study Design
- Study Type: INTERVENTIONAL
- Allocation: RANDOMIZED
- Model: PARALLEL
- Masking: DOUBLE
- Enrollment: 64 participants
Interventions
- DRUG: Combination therapy — Macitentan 10mg, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
- DRUG: Monotherapy — Macitentan placebo, Dapagliflozin 10mg or 5mg po tablet q.d. in 24 weeks
Primary Outcomes
- Hierarchical outcome component(Change in PVR, Change in NT-proBNP, Change in 6MWD, Change in KCCQ-CSS) (Baseline, 24 week)
Secondary Outcomes
- Change in Pulmonary Vascular Resistance (PVR) from Baseline to Week 24 (Baseline, 24 week)
- Change in Mean Pulmonary Arterial Pressure (mPAP) from Baseline to Week 24 (Baseline, 24 week)
- Change in Pulmonary Arterial Wedge Pressure (PAWP) from Baseline to Week 24 (Baseline, 24 week)
- Change in 6-Minute Walk Distance from Baseline to Week 24 (Baseline, 24 week)
- Change in Oxygen Saturation (SpO2) Difference Before and After 6-Minute Walk Test from Baseline to Week 24 (Baseline, 24 week)
Trial Locations
- Pusan National University Hospital, Busan, South Korea
- Chungbuk National University Hospital, Chungju, South Korea
- Keimyung University Dongsan Hospital, Daegu, South Korea
- Chungnam National University Hospital, Daejeon, South Korea
- Chonnam National University Hospital, Gwangju, South Korea
- Incheon Sejong Hospital, Incheon, South Korea
- Gachon University Gil Hospital, Incheon, South Korea
- Seoul National University Hospital, Seoul, South Korea
- Yonsei University Health System, Severance Hospital, Seoul, South Korea
- Asan Medical Center, Seoul, South Korea
- ...and 5 more locations
More Combined Pre- and Post-capillary Pulmonary Hypertension Trials
View all Combined Pre- and Post-capillary Pulmonary Hypertension clinical trials
AI-generated analysis for educational purposes only. This is not medical advice. Discuss clinical trial participation with your doctor. Data sourced from ClinicalTrials.gov.